Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
基本信息
- 批准号:10295165
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-10-01 至 2023-09-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs disease modelAnimal ModelAntiepileptic AgentsAntipsychotic AgentsAttentionBehavioralBinding ProteinsBiologicalBiological MarkersCharacteristicsClinicalCognitionCognitiveCognitive deficitsCrossover DesignDataDiseaseDoseDouble-Blind MethodEpilepsyFunctional ImagingFunctional Magnetic Resonance ImagingFutureGoalsHippocampus (Brain)HumanHyperactivityImpaired cognitionInvestigationKnowledgeLevetiracetamMemoryMetabolismMonitorNeurobehavioral ManifestationsNeurobiologyNeurocognitiveNeurological statusNeuronsNeuropsychologyOccupationsOutcomeOutcome MeasurePathologyPatientsPerformancePharmaceutical PreparationsPharmacologyPharmacotherapyPlacebo ControlPopulationPrediction of Response to TherapyPublishingQuality of lifeRandomizedResearchRestRodent ModelSchizophreniaSymptomsTestingVeteransWorkbaseclinical efficacycognitive enhancementcognitive functioncognitive loadcognitive performancecognitive testingdesigndisabilityeffective therapyexperimental studygray matterimaging studyimprovedinterestmemory processmild cognitive impairmentmouse modelnovelnovel strategiesnovel therapeuticsopen labelpreventprocessing speedpsychosocialrecruitresponsetargeted biomarkertherapeutic developmenttreatment strategy
项目摘要
Schizophrenia is a leading cause of disability for Veterans. Due to the lack of an effective
treatment, Veterans with schizophrenia suffer a myriad of cognitive impairments, including deficits in
attention, memory, and processing speed. As a result, patients struggle on the job, in relationships, and in
day-to-day activities, contributing to an overall poor quality of life.
New treatments for cognitive dysfunction in schizophrenia clearly are needed. A potentially
powerful approach for developing and evaluating novel therapeutics is to combine
behavioral/neurocognitive outcome measures with functional imaging of a drug's effects on a
neurobiological marker. A topic of current great interest in schizophrenia research is the finding that
patients show increased activity of the hippocampus, particularly at “rest” or in other similar conditions of
low cognitive load. This increased activity has been hypothesized to prevent further recruitment of the
region as task demands increase, contributing to cognitive dysfunction. Furthermore, recently published
work has demonstrated that cognitive performance in schizophrenia is negatively correlated with resting
hippocampal activity. It follows that a drug treatment capable of reducing resting hippocampal activity may
improve cognition in patients.
Recent findings have demonstrated that low doses of the anti-epileptic drug levetiracetam (LEV)
reduce hippocampal hyperactivity and improve performance on a memory task in patients with mild
cognitive impairment. LEV also reduces hippocampal hyperactivity in mouse models of Alzheimer's
disease, an effect also recently shown in a mouse model of schizophrenia. Unlike other anti-epileptics,
LEV improves cognition in epilepsy patients. The drug is well tolerated at doses several fold higher than
that used to demonstrate its effects on the hippocampus. As such, it is possible that low-dose LEV may be
a useful strategy for reducing hippocampal hyperactivity and improving cognition in schizophrenia.
A thorough investigation of the hypothesis that LEV will reduce hippocampal hyperactivity and
improve cognition in Veterans with schizophrenia is proposed. In the first Aim, functional magnetic
resonance imaging will be used to determine the lowest dose at which LEV engages the biological target
of interest, hippocampal hyperactivity. This Aim will use a 2-week open-label crossover design to examine
the effects of two low doses of LEV (125 mg b.i.d. and [62.5] mg b.i.d.) on resting hippocampal activity in
schizophrenia. The second Aim will then use the dose optimized in Aim 1 in a 4-week placebo-controlled,
double-blind, randomized, parallel design to assess the cognitive effects of LEV, utilizing the Repeatable
Battery for the Assessment of Neurological Status (RBANS). The relationship between LEV effects on
hippocampal activity and its effects on cognitive performance also will be examined.
This project will use a novel approach to investigate the efficacy of a potential new pharmacologic
target in schizophrenia. The project also will evaluate hippocampal hyperactivity as a biomarker in
schizophrenia by examining its ability to predict treatment response. Understanding the cognitive and
neurobiological effects of LEV will provide an early indication of whether LEV can be repurposed to
enhance cognitive function in Veterans with schizophrenia.
精神分裂症是导致退伍军人残疾的主要原因。由于缺乏一个有效的
在接受治疗的过程中,患有精神分裂症的退伍军人遭受了无数的认知障碍,包括精神障碍
注意力、记忆力和处理速度。因此,患者在工作中、人际关系中以及在
日常活动,导致整体生活质量不佳。
精神分裂症的认知功能障碍显然需要新的治疗方法。一个潜在的
开发和评估新疗法的有效途径是联合
用药物作用的功能成像测量行为/神经认知结果
神经生物标志物。目前对精神分裂症研究非常感兴趣的一个话题是发现
患者表现出海马体活动增强,特别是在“休息”或其他类似的情况下。
认知负荷低。这种增加的活动被认为是为了防止进一步招募
随着任务需求的增加,导致认知功能障碍。此外,最近出版的
研究表明,精神分裂症患者的认知能力与休息时间呈负相关
海马区活动。因此,一种能够减少静息海马区活动的药物治疗可能会
改善患者的认知。
最近的研究结果表明,低剂量的抗癫痫药物左乙拉西坦(Lev)
减少轻度痴呆患者的海马区过度活动并改善记忆任务的表现
认知障碍。LEV还可减少阿尔茨海默病小鼠模型的海马区多动
疾病,这一效应最近也在精神分裂症的小鼠模型中表现出来。与其他抗癫痫药物不同,
LEV可改善癫痫患者的认知功能。这种药物的耐受性很好,剂量比
用来证明它对海马体的影响。因此,低剂量的LEV有可能是
减少精神分裂症患者海马区过度活动和改善认知的有效策略。
对LEV将减少海马区过度活动和
目的:提高退伍军人精神分裂症患者的认知水平。在第一个目标中,功能磁性
磁共振成像将被用来确定LEV与生物靶点接触的最低剂量
有趣的是,海马区过度活跃。这一目标将使用为期两周的开放标签交叉设计来检查
两个小剂量的利福平(125 mg,tid。和[62.5]mg,b.i.d。)大鼠静息状态下海马区活动的研究
精神分裂症。第二个目标将在为期4周的安慰剂对照中使用目标1中优化的剂量,
双盲、随机、平行设计,评估LEV的认知效应,利用可重复的
神经状态评估电池(RBANS)。LEV效应与细胞周期的关系
海马体的活动及其对认知能力的影响也将被研究。
这个项目将使用一种新的方法来研究一种潜在的新药理的疗效。
精神分裂症的目标。该项目还将评估海马区过度活动作为一种生物标志物
通过检测其预测治疗反应的能力来诊断精神分裂症。了解认知和
LEV的神经生物学效应将为LEV是否可以被改变用途提供早期迹象
增强退伍军人精神分裂症患者的认知功能
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JASON R TREGELLAS其他文献
JASON R TREGELLAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JASON R TREGELLAS', 18)}}的其他基金
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10551293 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10209808 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10388376 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10038801 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10671447 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
8960808 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
9767131 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
9307811 - 财政年份:2015
- 资助金额:
-- - 项目类别:
相似海外基金
Elucidation of mucosal healing mechanisms through the construction of a human Crohn 's disease model
通过构建人类克罗恩病模型阐明粘膜愈合机制
- 批准号:
20K08378 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)